Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea.

Ha Young JangIn-Wha KimJung Mi Oh

Published in: Pharmaceutics (2023)

The usage of empagliflozin in diabetic CKD patients shows a significant reduction in many adverse outcomes compared to sitagliptin, but with an increased risk of genital tract infections. These findings provide evidence for future clinical decision-making around the use of empagliflozin in Asian CKD patients.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
decision making
peritoneal dialysis
type diabetes
prognostic factors
patient reported outcomes
wound healing